CLINICAL_TRIALS
trial_result
· 2024-01-16
Clinical Trial Update: Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines [Phase 3]
Summary
A long-term extension phase 3 trial evaluating MBA-P01 for moderate to severe glabellar lines has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Medytox Korea | Conditions: Glabellar Frown Lines | Phase 3 | Status: COMPLETED